ArticleBMC molecular and cell biology2026
Human urine-derived stem exosomes inhibit inflammation and oxidative stress in sepsis-related acute kidney injury.
Article in BMC molecular and cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracellular vesicles mediate immune regulation in acute kidney injury.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThe objective of this study was to explore the mechanisms by which urine - derived stem cell exosomes (USCexo) alleviate sepsis - related acute kidney injury (SAKI), as acute kidney injury often complicates sepsis with unclear role of USCexo in SAKI while stem cell exosomes show potential in AKI treatment.
methodsHuman urine - derived stem cells (USCs) were isolated from human urine and characterized via flow cytometry. A sepsis - related acute kidney injury mouse model was induced by cecal ligation and puncture (CLP). The mice were divided into a control group receiving phosphate - buffered saline (PBS) and an experimental group receiving USCexo via tail vein injection. Survival rate, renal damage evaluated by HE staining, and renal function assessed by sCr and BUN levels were measured. Renal RNA was extracted to analyze apoptosis and oxidative stress. In vitro, qRT - PCR was used to assess the inflammatory response in macrophages treated with USCexo.
resultsTreatment with USC - derived exosomes led to a reduction in the levels of pathological injury, sCr, and BUN. It inhibited renal cell apoptosis and oxidative stress, decreased the infiltration of inflammatory cells, and protected renal function in SAKI mice. Additionally, USCexo suppressed the inflammatory response of primary peritoneal macrophages induced by lipopolysaccharide (LPS).
conclusionsUSC - derived exosomes protect against SAKI by inhibiting oxidative stress and inflammation, which provides a theoretical basis for the potential use of USCexo in the treatment of SAKI. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.